title: Tailor-made renal cell carcinoma vaccines.
abstract: Cancer vaccines are beginning to show signs of clinical activity, but major uncertainties remain regarding antigen selection, strategy for immune stimulation, patient stratification, and monitoring of elicited response. A new study of peptide vaccines in advanced renal cell carcinoma patients provides important insights into these central issues.
authors.affiliation: Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA. glenn_dranoff@dfci.harvard.edu
authors.forename: Glenn
authors.initials: G
authors.lastname: Dranoff
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000628:therapy*; D017322:Clinical Trials, Phase II as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D007680:Kidney Neoplasms / Q000276:immunology / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D022223:Vaccines, Subunit / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D022223:Vaccines, Subunit; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide